Table 1.
Baseline characteristics.
| Characteristic | Pre-ICI era n = 32 (%) |
Post-ICI era n = 94 (%) |
|
|---|---|---|---|
| Age | median (range) | 62 (34–89) | 65 (22–87) |
| Sex | male female |
14 (43.8%) 18 (56.3%) |
47 (50.0%) 47 (50.0%) |
| AJCC stage at diagnosis | stage I stage IIA stage IIB stage IIIA stage IIIB stage IIIC stage IV unknown |
1 (3.1%) 11 (34.4%) 11 (34.4%) 6 (18.8%) 2 (6.3%) 0 (0%) 1 (3.1%) 0 (0%) |
7 (7.4%) 25 (26.6%) 24 (25.5%) 20 (21.3%) 10 (10.6%) 3 (3.2%) 4 (4.3%) 1 (1.1%) |
| ECOG performance status |
0 1 2 3 unknown |
11 (57.9%) 5 (26.3%) 2 (10.5%) 1 (5.3%) 13 |
53 (60.2%) 25 (28.4%) 9 (10.2%) 1 (1.1%) 6 |
| Metastatic sites | liver only extrahepatic only liver + extrahepatic |
15 (46.9%) 2 (6.3%) 15 (46.9%) |
39 (41.5%) 8 (8.5%) 47 (50.0%) |
| LDH | LDH ≤ ULN LDH 1-2× ULN LDH > 2× ULN unknown |
4 (25.0%) 6 (37.5%) 6 (37.5%) 16 |
34 (38.2%) 33 (37.1%) 22 (24.7%) 5 |
| Time from primary diagnosis to metastatic disease | <1 year 1–3 years >3 years |
3 (9.4%) 10 (31.3%) 19 (59.4%) |
22 (23.4%) 27 (28.7%) 45 (47.9%) |
| Time to start systemic treatment * | <6 months 6–12 months >12 months |
30 (96.7%) 1 (3.2%) 0 (0%) |
75 (86.2%) 7 (8.0%) 5 (5.7%) |
* Calculated from the diagnosis of metastatic disease, excluding patients who did not receive systemic treatment. AJCC, American Joint Committee on Cancer; ECOG performance status, Eastern cooperative oncology group performance status; ICI, immune checkpoint inhibitor: LDH, lactate dehydrogenase; ULN, upper limit of normal.